Cambridge Healthtech Institute’s 2nd Annual

Emerging Indications for Therapeutic Antibodies
( 治疗用抗体的新适应症 )

R&D Advances in Non-Cancer Indications for Antibodies and Other Biotherapeutics



Significant scientific advances in the fields of immunology and protein science are driving the development of biotherapeutic drugs in a growing range of therapeutic areas beyond oncology. These advances are driving the identification of new and unique targets, new approaches to developing biotherapeutics for unserved medical needs, methods of binding to illusive targets and translational science for patient stratification and drug development for niche indications. The PEGS Emerging Indications for Therapeutic Antibodies conference provides a forum for research organizations with diverse portfolios to explore new science and technology in the development of a next generation of safe and effective therapeutics in an important set of emerging indications.

Preliminary Agenda


An Overview of mAb Approaches for GPCRs and Ion Channels

Narender Gavva, Director, Early Target Discovery, Takeda

Production of Inhibitory Antibody Against Claudin-5 Using Engineered Membrane Protein Antigens

Hiroyuki Takeda, PhD, Associate Professor and Principal Investigator, Division of Protea-Drug-Discovery Sciences, Proteo-Science Center, Ehime University, Japan

Pipeline Update on GPCR and Ion Channel Antibodies

Catherine Hutchings, PhD, Independent Consultant, United Kingdom


Close Encounters of the T Cell Kind: Induction and Maintenance of Regulatory T Cells with Orally Administered Biomaterials

Tarek Fahmy, PhD, Associate Professor of Biomedical Engineering and Immunobiology, Yale University

Antibody Therapeutics for Complement Mediated Diseases

Thomas Dudler, PhD, Product Team Leader, Omeros

KEYNOTE PRESENTATION: Lessons Learned from Humira

Jochen Salfeld, PhD, Vice President Global Biologics, AbbVie


Direct Targeting Cytosolic Proteins by IgG-Format Antibody

Yong Sung Kim, PhD, Professor, Molecular Science & Technology, Ajou University, Korea

Targeting Microvesicles Loaded with Drugs to Arthritic Joints Using Antibodies Specific to Arthritic Cartilage

Ahuva Nissim, PhD, Professor, Antibody and Therapeutic Engineering, Biochemical Pharmacology, Queen Mary University, United Kingdom

V565, an Oral Anti-TNFα Domain Antibody for IBD

Kevin Roberts, PhD, Senior Scientist and Project Leader, VHsquared, United Kingdom


B-Cell Cloning and Screening to Identify New Antibodies and Understandings of Adaptive Immune Response

Patrick C. Wilson, PhD, Associate Professor, Medicine, Knapp Center for Lupus and Immunology Research, Committee on Immunology, University of Chicago

Structural Investigation of Human S. Aureus-Targeting Antibodies that Bind Wall Teichoic Acid

Patrick Lupardus, PhD, Senior Scientist and Group Leader, Genentech

Structure-Based Approaches for the Discovery of Potent Antibodies against Malaria Antigens

Jean-Philippe Julien, PhD, Canada Research Chair in Structural Immunology, The Hospital for Sick Children Research Institute


Canakinumab for Atherosclerotic Disease

Paul M. Ridker, MD, Director, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital

Targeting FcRn in IgG Autoantibody-Driven Diseases

Anthony Shock, PhD, Director, Immunology Research, UCB, United Kingdom

Completing the Immunity Cycle by Developing Myeloid Immunotherapies

Tatiana Novobrantseva, PhD, Co-Founder, Head of Research and Development, Verseau Therapeutics

Antagonistic Antibodies Used to Establish the Key Role for IL-13 Signaling Via the Type 2 IL-4 Receptor in Experimental Atopic Dermatitis

Itai Benhar, PhD, Professor, Molecular Cell Biology and Biotechnology. Tel-Aviv University

ProImmunePresentation to be Announced

* 活动内容有可能不事先告知作更动及调整。

Choose your language

Premier Sponsors